U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

The drugs were first approved to treat type 2 diabetes – and that's what the FDA said daily injections of liraglutide could ...

The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes ...

European markets were trading higher on Tuesday, in a shortened trading session for Christmas Eve. The pan-European Stoxx 600 ...

Lilly and Novo still dominate the market for weight-loss and diabetes drugs, but the race is heating up in more ways than one ...

Pfizer's oncology promises are several years from being actualized. Read why investors shouldn't assume that a sustained ...

Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

The FDA initially rejected the marketing application for Alhemo in 2022, asking for additional data on dosing and monitoring.

The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...

Authorized generics are the exact copies of branded drugs, sold by another company with the branded drug manufacturer’s ...